Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Signs Academic Collaboration Pact With Peking University To Support Translational R&D Center In Shenzhen

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - After unveiling a plan to build a research and development center in Wuhan last week, Pfizer announced it inked an agreement with Peking University Dec. 1 to fund the university's research projects and to build a translational research and drug discovery center in PKU's Graduate School in Shenzhen, a Chinese city that borders the former British enclave of Hong Kong
Advertisement

Related Content

Today Asia, Tomorrow The World? AstraZeneca Looks To Align R&D Strategy Across Emerging Markets
Today Asia, Tomorrow The World? AstraZeneca Looks To Align R&D Strategy Across Emerging Markets
Early Days For Discovery Collaborations With Academia In China - China Healthcare Investment Conference
Early Days For Discovery Collaborations With Academia In China - China Healthcare Investment Conference
China's CRO Industry Pulling Out All Stops In The Year Of The Tiger (Part 1 of 2)
China's CRO Industry Pulling Out All Stops In The Year Of The Tiger (Part 1 of 2)
Pfizer Signs MOU With Wuhan To Establish First R&D Center In Midwest China; Ranks Number One In China
Pfizer Signs MOU With Wuhan To Establish First R&D Center In Midwest China; Ranks Number One In China
Pfizer R&D In China: Building A Virtual R&D Network
Pfizer Collaboration With University Of California Spawns New Research
Advertisement
UsernamePublicRestriction

Register

SC070644

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel